Jason Garland Sells 733 Shares of Repligen (NASDAQ:RGEN) Stock

Repligen Corporation (NASDAQ:RGEN) CFO Jason Garland sold 733 shares of Repligen stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total transaction of $106,285.00. Following the completion of the sale, the chief financial officer owned 19,359 shares of the company’s stock, valued at $2,807,055. This represents a 3.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Repligen Stock Up 1.2%

Shares of Repligen stock traded up $1.78 during trading on Friday, reaching $147.01. 1,965,039 shares of the company traded hands, compared to its average volume of 981,841. The firm has a market capitalization of $8.29 billion, a PE ratio of 163.35, a P/E/G ratio of 2.67 and a beta of 1.09. Repligen Corporation has a 1-year low of $100.99 and a 1-year high of $175.77. The company has a 50 day moving average price of $122.54 and a 200-day moving average price of $135.46. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.20 and a quick ratio of 7.78.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.10. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The business had revenue of $194.25 million during the quarter, compared to analysts’ expectations of $192.05 million. During the same period last year, the company posted $0.39 earnings per share. The business’s quarterly revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, equities research analysts expect that Repligen Corporation will post 1.99 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on RGEN. Jefferies Financial Group reaffirmed a “hold” rating and issued a $142.00 target price on shares of Repligen in a research report on Tuesday, May 5th. Canaccord Genuity Group reduced their price objective on Repligen from $165.00 to $145.00 and set a “hold” rating for the company in a research note on Monday, April 20th. Royal Bank Of Canada assumed coverage on Repligen in a report on Thursday, May 14th. They set an “outperform” rating and a $160.00 price objective for the company. Wall Street Zen lowered Repligen from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Finally, HC Wainwright lifted their price target on shares of Repligen from $180.00 to $208.00 and gave the company a “buy” rating in a research report on Monday, March 23rd. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $164.64.

Hedge Funds Weigh In On Repligen

Several large investors have recently added to or reduced their stakes in RGEN. Measured Wealth Private Client Group LLC acquired a new position in Repligen during the 3rd quarter valued at about $29,000. Bayforest Capital Ltd purchased a new stake in shares of Repligen in the fourth quarter worth approximately $32,000. Rachor Investment Advisory Services LLC purchased a new stake in shares of Repligen in the fourth quarter worth approximately $33,000. Los Angeles Capital Management LLC bought a new position in shares of Repligen in the fourth quarter valued at approximately $36,000. Finally, Farther Finance Advisors LLC lifted its holdings in shares of Repligen by 61.8% in the fourth quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 128 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.